Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
Authors:
- 1 December 2008
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 32 (12) , 1849-1856
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Mechanisms of killing by anti-CD20 monoclonal antibodiesMolecular Immunology, 2007
- Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997Journal of Clinical Oncology, 2007
- Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001Blood, 2006
- Update on risk-stratified management for chronic lymphocytic leukemiaLeukemia & Lymphoma, 2006
- Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicityEuropean Journal of Pharmacology, 2005
- Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood, 2004
- Complement function in mAb-mediated cancer immunotherapyTrends in Immunology, 2004
- Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood, 2003
- An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximabBlood, 2003
- The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis inductionBlood, 2002